Montreal, Canada / Hong Kong, SAR – February 1st, 2015 Luqa Pharmaceuticals (“Luqa”), the China focused specialty pharmaceutical company, today announces the signing of a licensing agreement with Paladin Labs Inc., an operating company of Endo International plc. Under the terms of the agreement, Luqa will own rights over Podofilm, a product indicated for the treatment of benign epitelial formations such as venereal warts, common warts, and benign papillomas in the People’s Republic of China, Hong Kong and Macau.
Podofilm is expected to rapidly become a key brand within Luqa’s strong portfolio of ethical dermatology products. The companies expect to make the product available in China within 2015.
“We are pleased to be partnering with Paladin for Podofilm in China”, stated Robert Braithwaite, CEO of Luqa Pharmaceuticals. “Podofilm is a strong fit for Luqa’s ethical dermatology franchise and we look forward to a long and successful collaboration with Paladin.”
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada’s leading specialty pharmaceutical companies. Paladin is an operating company of Endo International plc, a global specialty healthcare company focused on improving the lives of patients while creating value. For more information about Paladin, please visit the Company’s web site at www.paladin-labs.com
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a fast-growing revenue generating company with a broad product portfolio and pipeline. We aim to become a leader in specialty care segments in China. Please visit us at www.luqapharma.com
T. +86 21 5237 6098